First Quadrant L P CA Takes $201,000 Position in Myriad Genetics, Inc. (MYGN)

First Quadrant L P CA purchased a new stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) in the 3rd quarter, HoldingsChannel reports. The fund purchased 4,361 shares of the company’s stock, valued at approximately $201,000.

Other hedge funds have also recently added to or reduced their stakes in the company. UBS Group AG raised its position in shares of Myriad Genetics by 265.1% in the 1st quarter. UBS Group AG now owns 146,336 shares of the company’s stock valued at $4,324,000 after purchasing an additional 106,258 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Myriad Genetics in the 1st quarter valued at approximately $306,000. LPL Financial LLC raised its position in shares of Myriad Genetics by 37.3% in the 1st quarter. LPL Financial LLC now owns 9,032 shares of the company’s stock valued at $267,000 after purchasing an additional 2,454 shares during the last quarter. Legal & General Group Plc raised its position in shares of Myriad Genetics by 3.0% in the 1st quarter. Legal & General Group Plc now owns 141,462 shares of the company’s stock valued at $4,185,000 after purchasing an additional 4,185 shares during the last quarter. Finally, Royal Bank of Canada raised its position in shares of Myriad Genetics by 59.5% in the 1st quarter. Royal Bank of Canada now owns 4,597 shares of the company’s stock valued at $136,000 after purchasing an additional 1,715 shares during the last quarter. 96.32% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:MYGN opened at $45.03 on Thursday. Myriad Genetics, Inc. has a twelve month low of $27.23 and a twelve month high of $50.44. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.86 and a current ratio of 3.19. The company has a market capitalization of $3.28 billion, a P/E ratio of 37.53, a price-to-earnings-growth ratio of 2.61 and a beta of 0.51.



Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, August 21st. The company reported $0.38 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.05. Myriad Genetics had a net margin of 17.69% and a return on equity of 9.78%. The company had revenue of $200.90 million for the quarter, compared to the consensus estimate of $195.93 million. During the same quarter in the prior year, the company earned $0.30 EPS. Myriad Genetics’s quarterly revenue was up .7% on a year-over-year basis. On average, analysts forecast that Myriad Genetics, Inc. will post 1.41 earnings per share for the current year.

Several equities analysts recently commented on MYGN shares. Barclays lowered shares of Myriad Genetics from an “equal weight” rating to an “underweight” rating and decreased their price objective for the company from $38.00 to $30.00 in a research report on Wednesday, September 5th. Morgan Stanley raised shares of Myriad Genetics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $35.00 to $55.00 in a research report on Wednesday, July 11th. Zacks Investment Research lowered shares of Myriad Genetics from a “buy” rating to a “sell” rating in a research report on Monday, August 27th. Bank of America increased their price objective on shares of Myriad Genetics from $20.00 to $31.00 and gave the company an “underperform” rating in a research report on Monday, July 16th. Finally, BidaskClub lowered shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 21st. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. Myriad Genetics presently has a consensus rating of “Hold” and an average target price of $40.60.

About Myriad Genetics

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Recommended Story: Asset Allocation and Your Retirement

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply